KARYOPHARM THERAPEUTICS INC. overview

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting PR Newswire NEWTON, Mass., April 24, 2024 Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates" NEWTON, Mass. , April 24, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., April 1, 2024 NEWTON, Mass. , April 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 79,800 restricted stock units (RSUs) to five newly-hired employees. These RSU awards were granted as of March 31, 2024 (the "Grant Date") pursuant...

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences PR Newswire NEWTON, Mass., March 6, 2024 NEWTON, Mass. , March 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., March 1, 2024 NEWTON, Mass. , March 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,250 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of February 29, 2024 (the "Grant Date")...

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress PR Newswire NEWTON, Mass., Feb. 29, 2024 – Total Revenue of $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company's Guidance – – Top-Line Data Readouts from Three Pivotal Phase 3 Trials Evaluating Selinexor in Endometrial Cancer, Myelofibrosis and Multiple Myeloma Expected in 2025 – – Company Provides Full-Year 2024...

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 PR Newswire NEWTON, Mass., Feb. 22, 2024 -- Conference Call Scheduled for Thursday, February 29, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , Feb. 22, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 29, 2024 ....

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., Feb. 1, 2024 NEWTON, Mass. , Feb. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 26,850 restricted stock units (RSUs) to seven newly-hired employees. These RSU awards were granted as of January 31, 2024 (the "Grant Date") pursuant...

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives PR Newswire NEWTON, Mass., Jan. 8, 2024 – Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, Endometrial Cancer and Myelofibrosis – – Preliminary Unaudited Full Year 2023 Total Revenue and U.S. XPOVIO ® (selinexor) Net Product Revenue Expected to be Approximately $146 Million and $112...